{ "items": [ "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n PROFILE OF CIRCADIANLY REGULATED METABOLIC GENES IN DYSTROPHIC HEART\n

\n \n \n \n \n\n \n \n \n

Betts CA. et al, (2018), HEART, 104, A4 - A4

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Antisense oligonucleotides: the next frontier for treatment of neurological disorders.\n

\n \n \n \n \n\n \n \n \n

Rinaldi C. and Wood MJA., (2018), Nat Rev Neurol, 14, 9 - 21

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Extracellular Vesicle Heterogeneity: Subpopulations, Isolation Techniques, and Diverse Functions in Cancer Progression.\n

\n \n \n \n \n\n \n \n \n

Willms E. et al, (2018), Front Immunol, 9

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-/-mdx mouse models of Duchenne muscular dystrophy.\n

\n \n \n \n \n\n \n \n \n

Blain AM. et al, (2018), PLoS One, 13

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Proteomic evaluation of Pip6a-PMO treatment for myotonic dystrophy type 1\n

\n \n \n \n \n\n \n \n \n

Holland A. et al, (2018), NEUROMUSCULAR DISORDERS, 28, S8 - S9

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Alpha-synuclein induces the unfolded protein response in Parkinson's disease SNCA triplication iPSC-derived neurons.\n

\n \n \n \n \n\n \n \n \n

Heman-Ackah SM. et al, (2017), Hum Mol Genet, 26, 4441 - 4450

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Biomarker Potential of Extracellular miRNAs in Duchenne Muscular Dystrophy.\n

\n \n \n \n \n\n \n \n \n

Coenen-Stass AML. et al, (2017), Trends Mol Med, 23, 989 - 1001

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Overwintering habitat links to summer reproductive success: intercontinental carry-over effects in a declining migratory bird revealed using stable isotope analysis\n

\n \n \n \n \n\n \n \n \n

Goodenough AE. et al, (2017), Bird Study, 64, 433 - 444

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape.\n

\n \n \n \n \n\n \n \n \n

Wood MJA. et al, (2017), Hum Mol Genet, 26, R151 - R159

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Reproducible and scalable purification of extracellular vesicles using combined bind-elute and size exclusion chromatography.\n

\n \n \n \n \n\n \n \n \n

Corso G. et al, (2017), Sci Rep, 7

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Therapeutic strategies for spinal muscular atrophy: SMN and beyond.\n

\n \n \n \n \n\n \n \n \n

Bowerman M. et al, (2017), Dis Model Mech, 10, 943 - 954

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Knockdown and replacement therapy mediated by artificial mirtrons in spinocerebellar ataxia 7.\n

\n \n \n \n \n\n \n \n \n

Curtis HJ. et al, (2017), Nucleic Acids Res, 45, 7870 - 7885

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n BRD3 and BRD4 BET Bromodomain Proteins Differentially Regulate Skeletal Myogenesis.\n

\n \n \n \n \n\n \n \n \n

Roberts TC. et al, (2017), Sci Rep, 7

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Functional Delivery of Lipid-Conjugated siRNA by Extracellular Vesicles.\n

\n \n \n \n \n\n \n \n \n

O'Loughlin AJ. et al, (2017), Mol Ther, 25, 1580 - 1587

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Targeting blood-brain-barrier transcytosis - perspectives for drug delivery.\n

\n \n \n \n \n\n \n \n \n

M\u00e4ger I. et al, (2017), Neuropharmacology, 120, 4 - 7

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Splice-Switching Therapy for Spinal Muscular Atrophy.\n

\n \n \n \n \n\n \n \n \n

Meijboom KE. et al, (2017), Genes (Basel), 8

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n Identification of a Peptide for Systemic Brain Delivery of a Morpholino Oligonucleotide in Mouse Models of Spinal Muscular Atrophy.\n

\n \n \n \n \n\n \n \n \n

Shabanpoor F. et al, (2017), Nucleic Acid Ther, 27, 130 - 143

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n
\n
\n \n \n

\n C9orf72 and RAB7L1 regulate vesicle trafficking in amyotrophic lateral sclerosis and frontotemporal dementia.\n

\n \n \n \n \n\n \n \n \n

Aoki Y. et al, (2017), Brain, 140, 887 - 897

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n \n
\n \n \n

\n C9ORF72 and RAB7L1 regulate vesicle trafficking in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia\n

\n \n \n \n \n\n \n \n \n

Manzano R. et al, (2017), NEUROMUSCULAR DISORDERS, 27, S31 - S32

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n
\n \n
\n \n \n

\n The glucocorticoid-KLF15-BCAA pathway as a novel therapeutic target for spinal muscular atrophy\n

\n \n \n \n \n\n \n \n \n

Walter LM. et al, (2017), NEUROMUSCULAR DISORDERS, 27, S28 - S29

\n \n \n \n

\n \n

\n \n \n
\n\n
\n\n
\n\n\n" ], "more": "\n\n \n \n Load More\n \n \n\n", "msg": "" }